Skip to main content

JDRF is undergoing a transformation.
We are becoming Breakthrough T1D in October.

breakthrought1d logo

New partnership provides affordable insulin for all in the USA

An historic deal has been agreed between JDRF International and partners, to deliver lower-cost insulin across the USA from 2024 to everyone – regardless of insurance status.
JDRF logo placeholder for author profile picture
Kate Lawton 3 March 2022

Insulin vials

Tackling the rising cost of insulin

The cost of a vial of insulin has tripled in the USA over the last ten years, with prices currently ranging from between $175 (£130) and $300 (£224) per vial, which could cost a person up to $1,000 (£750) a month.

An estimated one in four people who are insulin dependent say they skip or ration their insulin because they cannot afford to pay this inflated price, potentially leading to severe consequences for their health, medical emergencies, or even death.

A groundbreaking partnership

This groundbreaking partnership between JDRF International – who are based in the USA – and other funders, means that Civica, a nonprofit generic drug manufacturing company, can manufacture and distribute biosimilar insulin for no more than $30 (£23) a vial, or $55 (£40) for a box of five pen cartridges. This is as much as 90% lower than existing costs.

To make this happen, JDRF International has agreed to underwrite the initial development costs, meaning that Civica is able to provide this low-cost option to people who need it.

Civica will develop biosimilars to three of the most commonly used insulins in the USA, to reach the most people possible: glargine (Lantus®), lispro (Humalog®), and aspart (Novolog®). Biosimilar insulin is highly similar to existing insulins that are already licensed for use and are just as effective.

These affordable insulins will be available from 2024 to allow time for development, clinical trials and FDA approval, amongst other logistical factors. Everyone – regardless of their health insurance status – will be able to access this affordable insulin at this cost. This distinguishes this programme from many other existing routes of access for affordable insulin.

JDRF UK’s Chief Executive, Karen Addington, said: “We are today proud of the impact that JDRF achieves: this partnership will help resolve some of the systemic health inequality for people living with type 1 diabetes in the USA.

“It is our hope that this initiative then has the potential to go on and save lives across the world. We know that this news today will resonate with so many of our supporters and stakeholders who live with type 1 or work to prevent, treat and cure type 1 diabetes.”

Read JDRFI’s press release.

Related news

Read more
Hybrid closed loop technology
Type 1 technology
19 December 2023

NICE Approves hybrid closed loop for the majority of people living with type 1 diabetes in England and Wales

In an historic advancement in the treatment of type 1 diabetes, the National Institute for Health and Care Excellence (NICE) today approves hybrid closed loop for the majority of people living with type 1 diabetes in England and Wales.

Read more
Nina Willer, who used hybrid closed loop technology through pregnancy, and her child.
Treatment research
7 November 2023

Hybrid closed loop technology set to be made available in England and Wales

The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.

Read more
T cell immune system
Research
6 November 2023

New research highlights the effectiveness of immune therapies for type 1 diabetes

The research, which was co-funded by JDRF, reveals that drugs that target the immune system offer very effective and rapid improvements in stabilising blood sugar levels, often within just three months.

Read more
Islet cells from human donors
Treatment research
20 April 2023

Transplanted beta cells avoid immune attack in mice with type 1 diabetes

Genetically engineered beta cells transplanted into mice with type 1 diabetes avoid immune system attack and stabilise blood glucose levels without immunosuppressants.